Krisztina Bencsik: Influence Statistics

Krisztina Bencsik

Krisztina Bencsik

Albert Szent-Györgyi Clinical Centre, Department of Neurology, Faculty of General Medicine, University of Szeged, 6725 Szeged, Hungary;, biernacki.tamas@med.u-szeged.hu, ...

Krisztina Bencsik: Expert Impact

Concepts for which Krisztina Bencsik has direct influence: Multiple sclerosis , Patients multiple sclerosis , Cerebrospinal fluid , Csongrád county , Exercise capacity , Gray matter atrophy , Fabry disease .

Krisztina Bencsik: KOL impact

Concepts related to the work of other authors for which for which Krisztina Bencsik has influence: Multiple sclerosis , Kynurenine pathway , Cognitive impairment , Central nervous , Kynurenic acid , Cerebrospinal fluid , Neuromyelitis optica .

KOL Resume for Krisztina Bencsik

Year
2022

Albert Szent-Györgyi Clinical Centre, Department of Neurology, Faculty of General Medicine, University of Szeged, 6725 Szeged, Hungary;, (T.B.);, (Z.K.);, (D.S.);, (J.F.);, (Z.F.-N.);, (P.F.);, (T.Z.K.);, (P.K.);, (K.B.)

2021

Department of Neurology, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary

2020

Department of Neurology, Faculty of General Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, H-6725 Szeged, Hungary;, (T.B.);, (D.S.);, (K.B.)

2019

Department of Neurology, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged, Hungary

2018

Szegedi Tudományegyetem, Neurológiai Klinika, Szeged.

2017

Department of Neurology, University of Szeged, H-6725, Szeged, Semmelweis u. 6, Hungary

Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szent-Györgyi Albert Klinikai Központ, Neurológiai Klinika, Szeged.

2016

Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Semmelweis u. 6, 6725, Szeged, Hungary

c University of Szeged.

2015

Department of Neurology, Faculty of General Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged, Hungary

2014

Albert Szent‐Györgyi Clinical Centre University of Szeged Department of Neurology Faculty of General Medicine Szeged Hungary

2013

Department of Neurology, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary

2012

Department of Neurology, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged 6725, Hungary; E-Mails:, (J.F.);, (K.B.);, (C.R.);, (S.B.);, (L.V.)

2010

Department of Neurology, Albert Szent-Györgyi Clinical Centre, University of Szeged, 6 Semmelweis u., 6725, Szeged, Hungary

2009

Department of Neurology, Albert Szent-Györgyi Clinical Centre, University of Szeged, 6 Semmelweis u., H-6725, Szeged, Hungary

2008

Department of Neurology, Albert Szent-Györgyi Medical and Pharmaceutical Center, University of Szeged, Szeged

2007

University of Szeged, Department of Neurology, Semmelweis u. 6, H-6725 Szeged, Hungary

6 Szegedi Tudományegyetem, Általános Orvostudományi Kar Neurológiai Klinika Szeged

2006

University of Szeged

2005

Department of Neurology, Albert Szent‐Györgyi Medical and Pharmaceutical Center, University of Szeged, Szeged, Hungary

2003

Departments of, Pediatrics and, Neurology, Albert Szent-Györgyi Medical School, University of Szeged, and, Neurology Research Group of the Hungarian Academy of Sciences and University of Szeged, Szeged, Hungary

2002

Department of Neurology and MTA‐SZTE Neurology Research Group, University of Szeged, Szeged, Hungary,

2001

Department of Neurology, Faculty of General Medicine, Albert Szent-Györgyi Medical and Pharmaceutical Center, University of Szeged, Hungary

1999

Department of Neurology, Albert Szent-Györgyi University Medical School, H-6701 Szeged, P.O. Box 397, Hungary Tel.: +36-62-455597, Fax: +36-62-455597, HU

Neurológiai Klinika, Szent-Györgyi Albert Orvostudományi Egyetem, Szeged.

1998

National Institute of Oncology, Department of Biochemistry, P.O Box 21, H-1525 Budapest, Hungary

1997

Department of Neurology and Psychiatry, Albert Szent‐Györgyi University Medical School, Szeged

1995

Department of Biochemistry , National Institute of Oncology H-1122 Budapest , Hungary

1990

Neurology Clinic, Albert Szent-Györgyi Medical University, Szeged, Hungary

Prominent publications by Krisztina Bencsik

KOL-Index: 15526 . BACKGROUND: The common symptoms of multiple sclerosis are fatigue, depression, cognitive dysfunction, pain and sexual dysfunction, which influence the health-related quality of life of the patients. OBJECTIVE: We aimed to determine the correlations between the health-related quality of life, the level of disability, fatigue and depression in glatiramer acetate-treated patients with ...
Known for Multiple Sclerosis | Fatigue Depression | Glatiramer Acetate | Quality Life
KOL-Index: 10763 . BACKGROUND: Multiple Sclerosis (MS) causes not only somatic, but also cognitive impairment regardless of the patients׳ age or the course of the disease. The Brief International Cognitive Assessment for MS (BICAMS) test, published in 2011, is a short cognitive questionnaire: a fast, reliable, sensitive and specific tool for the evaluation of the patients׳ cognitive state. OBJECTIVES: Our ...
Known for Multiple Sclerosis | Cognitive Impairment | Bicams Test | Quality Life
KOL-Index: 8532 . Objective: Cortical pathology, periventricular demyelination, and lesion formation in multiple sclerosis (MS) are related (Hypothesis 1). Factors in the cerebrospinal fluid close to these compartments could possibly drive the parallel processes. Alternatively, the cortical atrophy could be caused by remote axonal transection (Hypothesis 2). Since MRI can differentiate between demyelination ...
Known for Gray Matter | Multiple Sclerosis | Radial Diffusivity | Imaging Mri
KOL-Index: 7001 . Biomarkers capable of predicting the clinical course and the rate of disease progression in multiple sclerosis are currently unavailable. Our objective was to examine if the levels of proteins associated with axonal and neuronal degeneration (Tau, p-Tau and β-amyloid(1-42)) and T-cell-mediated autoimmunity (osteopontin) are altered in the cerebrospinal fluid (CSF) of MS patients, and to ...
Known for Multiple Sclerosis | Csf Levels | Enzyme Linked | Amyloid Beta
KOL-Index: 6762 . OBJECTIVE: The aim of this study was to determine the prevalence of multiple sclerosis (MS) in the population of Csongrád County, Hungary (400,128 inhabitants) and to determine the functional status (based on the Expanded Disability Status Scale; EDSS) of the patients according to the clinical forms of the disease. METHODS: The diagnosis was established with the aid of the Poser diagnostic ...
Known for Csongrád County | Multiple Sclerosis | Clinical Forms | Relapsing Remitting
KOL-Index: 6523 . Tryptophan and its metabolites are of great interest in understanding the pathogenesis of multiple sclerosis (MS). The total levels of tryptophan and its metabolites, kynurenine and kynurenic acid were determined in plasma by capillary liquid chromatography electrospray ionisation tandem mass spectrometry. This is the first report of the plasma levels of these analytes in healthy controls ...
Known for Multiple Sclerosis | Metabolites Kynurenine | Kynurenic Acid | Tryptophan Metabolism
KOL-Index: 6180 . Health-related quality of life measurements are gaining more importance in the study and clinical practice of multiple sclerosis. The aim of our study was the adaptation of the Multiple Sclerosis Quality of Life Instrument (MSQOL-54) in Hungarian. The study was carried out at the Department of Neurology, University of Szeged and two other multiple sclerosis centers. The Hungarian ...
Known for Multiple Sclerosis | Quality Life | Msqol54 Instrument | Hungarian Version
KOL-Index: 6106 . BACKGROUND: Health-related quality of life (HRQoL) is lower in people with multiple sclerosis (PwMS) compared to the healthy population, psychological symptoms accompanying multiple sclerosis (MS) have a serious impact on the HRQoL of PwMS. Data regarding the subject, however, remain conflicting. OBJECTIVES: To evaluate the patients' sociodemographic attributes, education, fatigue, ...
Known for Multiple Sclerosis | Fatigue Depression | Cognitive Impairment | Quality Life
KOL-Index: 5638 . Tryptophan is one of the essential amino acids, 80% of which is catabolised in the extrahepatic tissues by indoleamine-2,3-dioxygenase (IDO), the rate-limiting enzyme of the kynurenine pathway. Metabolites along the kynurenine pathway have been implicated to play a role in the pathomechanism of neuroinflammatory and neurodegenerative disorders. Changes in the concentration levels of ...
Known for Multiple Sclerosis | Kynurenine Pathway | Amyotrophic Lateral | Neurodegenerative Diseases
KOL-Index: 5446 . PurposeFatigue is one of the most frequent complaints of patients with multiple sclerosis (MS). The Fatigue Impact Scale (FIS), one of the 30 available fatigue questionnaires, is commonly applied because it evaluates multidimensional aspects of fatigue. The main purposes of this study were to test the validity, test–retest reliability, and internal consistency of the Hungarian version of ...
Known for Fatigue Impact Scale | Patients Multiple Sclerosis | Internal Consistency | Hungarian Version
KOL-Index: 5365 . Tumour necrosis factor alpha (TNF-alpha) is associated with clinical activity in relapsing-remitting multiple sclerosis (RRMS) and the development of progressive disease. Our aim was to investigate the TNF-alpha -376 polymorphism in primary progressive MS (PPMS) patients. Polymerase chain reaction and restriction fragment length polymorphism were carried out on 45 PPMS patients, 45 age and ...
Known for Multiple Sclerosis | Necrosis Factor | Alpha Gene | Primary Progressive
KOL-Index: 5324 . Over the past years, an increasing amount of evidence has emerged in support of the kynurenine pathway's (KP) pivotal role in the pathogenesis of several neurodegenerative, psychiatric, vascular and autoimmune diseases. Different neuroactive metabolites of the KP are known to exert opposite effects on neurons, some being neuroprotective (e.g., picolinic acid, kynurenic acid, and the ...
Known for Multiple Sclerosis | Kynurenic Acid | Kynurenine Pathway | Metabolites Enzymes
KOL-Index: 5205 . The effects of a pharmacological blockade of the mu opiate receptors on the manifestation of tonic-clonic seizures were investigated in freely moving animals. 4-aminopyridine, a specific blocker of the neuronal K+ channels was used to produce generalized convulsions. After pretreatment of adult rats with 1 mg/kg naltrexone HCl, 3, 5, 7, 9, 14 mg/kg 4-aminopyridine was injected ...
Known for Aminopyridine Seizures | Adult Rats | Specific Blocker | Response Relationship
KOL-Index: 5106 . The pathogenesis of multiple sclerosis (MS), a devastating neuroinflammatory disorder of the central nervous system, has been presumed to involve the possible importance of the receptor for advanced glycation end products (RAGE). The aim of this study was to investigate the relevance of the genetic polymorphisms of RAGE in MS patients. A total of 168 patients with MS were enrolled; 136 ...
Known for Multiple Sclerosis | Rage Gene | Central Nervous | Transcriptional Activity
KOL-Index: 5049 . PRINCIPLES: Apolipoprotein E (ApoE), an important glycoprotein in the transport, uptake and redistribution of cholesterol, is necessary in nerve tissue repair. The APOE gene (APOE) is involved in neurodegenerative diseases, the best-known association being that between the APOE ε4 allele and Alzheimer's disease. Multiple sclerosis (MS) is a chronic inflammatory neurological disease. The ...
Known for Primary Progressive | Ε2 Allele | Apoe Gene | Multiple Sclerosis

Key People For Multiple Sclerosis

Top KOLs in the world
#1
Alanda K Thompson
multiple sclerosis spinal cord magnetic resonance
#2
Chris H Polman
multiple sclerosis magnetic resonance spinal cord
#3
Fred D Lublin
multiple sclerosis glatiramer acetate monoclonal antibodies
#4
Ludwig Kappos
multiple sclerosis disability progression magnetic resonance
#5
Massimo Filippi
multiple sclerosis magnetic resonance cervical cord
#6
Hans‐Peter Hartung
multiple sclerosis chronic inflammatory schwann cells

Albert Szent-Györgyi Clinical Centre, Department of Neurology, Faculty of General Medicine, University of Szeged, 6725 Szeged, Hungary;, biernacki.tamas@med.u-szeged.hu, (T.B.);, zsofia.kokas@med.u-szeged.huzsiofia, (Z.K.);, sandi.daniel@med.u-szeged